Intravenous r-TPA in vertebrobasilar acute infarcts.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15159494.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Presented are the clinical data of 18 consecutive patients who were treated by IV recombinant tissue plasminogen activator (r-TPA) for suspected vertebrobasilar (VB) acute ischemia within 7 hours. The mean delay for treatment was 5 +/- 3.6 hours. Mean baseline NIH Stroke Scale score was 17 +/- 4. At 3 months, 10 patients were independent (modified Rankin Scale [mRS] score = 0 to 2), whereas 8 patients showed a poor outcome (mRs = 3 to 6). IV r-TPA in VB ischemia in a 7-hour window may be safe and efficient.
Medical subject headings
- Fibrinolytic Agents
- Thrombolytic Therapy
- Tissue Plasminogen Activator
- Vertebrobasilar Insufficiency